Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The role of beta-cell crinophagy in generating diabetogenic neoepitopes

Award Number: R01DK134437
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/18/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

The role of beta-cell crinophagy in generating diabetogenic neoepitopes - ABSTRACT Autoimmune diseases affect more than 20 million people in the United States, and the worldwide prevalence is rising. Patients usually suffer from a lifetime of deteriorating illness because no cures are available for most autoimmune diseases, including type 1 diabetes. Addressing this formidable challenge requires a better understanding of the pathogenic elements eliciting autoreactive responses. Although extensive studies have examined the role of native antigens, whether neoantigens/neoepitopes function to drive the autoimmune process remains poorly understood. The identity of neoantigens, especially post-translational modifications (PTMs) responsible for generating immunogenic neoepitopes, requires a critical examination. Endocrine tissues are commonly targeted by autoimmunity. Diverse endocrine cells use the crinophagic pathway to dispose of excessive amounts of secretory proteins to maintain cellular homeostasis. In this process, the regular secretory granules are directly fused to lysosomes. The resulting vesicle, crinophagic bodies, or crinosomes, are enriched with catabolized peptide segments. In type 1 diabetes, a deteriorating autoimmune disease targeting the insulin-producing β cells in pancreatic islets, crinosomes function as an antigen source providing native peptides for recognition by pathogenic CD4 T cells. Our recent examination by immunopeptidomics uncovered diverse PTMs in crinosome-derived peptides, indicating that crinosomes are a specialized repository of potential neoantigens and neoepitopes related to type 1 diabetes. A novel neoepitope family, C19S (cysteine-to-serine conversion in the insulin B-chain), became progressively prominent along with the development of the diabetic autoimmune process. Most importantly, we identified highly compatible sequences of C19S in mice and humans with T1D. In mice, C19S can be recognized by previously unidentified CD4 T cells distinct from those reactive to the native epitope. It is therefore necessary to determine the pathogenicity of the autoreactive T cells targeting C19S. Furthermore, as a representative neoepitope family, C19S provides a setpoint for delineating how β-cell crinophagy functions as a novel pathogenic component in T1D. C19S may initiate a feed-forward loop in T1D pathogenesis by linking β-cell stress with autoimmunity. We also propose to assess translational applications of C19S in human crinophagy and T cell pathobiology. These analyses may lead to a broad identification of neoepitopes generated by human crinophagy, which may serve as valuable targets for T1D pathogenesis and therapeutics. Analysis of potential C19S-reactive T cells in human PBMCs may extend our knowledge of autoimmune pathogenesis beyond the current paradigm defined by native antigens.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $574,493 )
2026	2026	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	4/27/2026	NON-COMPETING CONTINUATION	$574,493
														Subtotal = $574,493

Issue Date FY: 2025 ( Subtotal = $611,650 )
2025	2025	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/14/2025	NON-COMPETING CONTINUATION	$611,650
														Subtotal = $611,650

Issue Date FY: 2024 ( Subtotal = $587,184 )
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	5/20/2024	NON-COMPETING CONTINUATION	$587,184
														Subtotal = $587,184

Issue Date FY: 2023 ( Subtotal = $611,651 )
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	9/15/2023	NEW	$0
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	8/17/2023	NEW	$611,651
														Subtotal = $611,651

Grand Total All Awards = $2,384,978

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of beta-cell crinophagy in generating diabetogenic neoepitopes

Award Number: R01DK134437

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/18/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer